Keywords
Rheumatoid arthritis
Erythrocyte sedimentation rate
C-reactive protein
Anti-citrullinated peptide antibody
Rheumatoid factor
Smoking
How to Cite
Abstract
Objective: To determine the factors associated with a poor prognosis in patients with RA at a 3rd level hospital.
Methods: Observational, analytical, longitudinal study of a cohort of patients with RA. The study continued for one year. The following were assessed as PPFs: sex, comorbidities, smoking, DAS 28 (disease activity), ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), ACCP (anti-citrullinated peptide antibody), RF (rheumatoid factor), and bone erosions. To statistical analysis: A Cox proportional hazards analysis was performed to analyze PPFs.
Results: A total of 260 patients were included, 26 failures and 234 censored, predominantly female sex, mean age 47 ± 11.7 years, the PPFs were: ACCP, late start of DMARD, and smoking. ACCP positive have 5.8 times the risk of escalating treatment, late DMARD have 4.6 times and those who smoked 7.7 times the risk.
Conclusions: Defining the PPFs remains a great challenge for researchers, however, it is imperative to identify them to predict the response to treatment and thus limit the functional and life damage of patients.
Keywords: Prognosis; Rheumatoid arthritis; Erythrocyte sedimentation rate; C-reactive protein; Anti-citrullinated peptide antibody; Rheumatoid factor; Smoking.
References
1. Deane KD, Holers VM. The Natural History of Rheumatoid Arthritis. Clin Ther 2019; 41 (7): 1256-1269. doi: 10.1016/j.clinthera.2019.04.028
2. Gui Y, Zhao J, Xie W, Huang H, et al. The universal presence of poor prognostic factors based on EULAR recommendations: A real-world study in 1164 Chinese RA patients. Joint Bone Spine 2023; 90 (6): 105633. doi: 10.1016/j.jbspin.2023.105633
3. Romão VC, Fonseca JE. Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review. Front Med (Lausanne) 2021; 8: 689698. doi: 10.3389/fmed.2021.689698
4. Alemao E, Litman HJ, Connolly SE, et al. Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. J Rheumatol 2018; 45 (10): 1353-1360. doi: 10.3899/jrheum.171050
5. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021; 73 (7): 924-939. doi: 10.1002/acr.24596
6. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [published correction appears in Ann Rheum Dis 2023; 82 (3): e76. doi: 10.1136/ard-2022-223356corr1.]. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356
7. Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and Management of Rheumatoid Arthritis. Clin Rev Allergy Immunol 2019; 56 (3): 333-345. doi:10.1007/s12016-018-8672-5
8. Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009; 11 (1): R7. doi: 10.1186/ar2591
9. Almoallim H, Al Saleh J, Badsha H, et al. A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East. Rheumatol Ther 2021; 8 (1): 1-16. doi: 10.1007/s40744-020-00252-1
10. Baganz L, Richter A, Albrecht K, et al. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. Semin Arthritis Rheum 2019; 48 (6): 976-982. doi: 10.1016/j.semarthrit.2018.09.003
11. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis 2017; 9 (10): 249-262. doi: 10.1177/1759720X17720366
12. Vittecoq O, Brevet P, Gerard B, Lequerre T. On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis. RMD Open 2024; 10 (3): e004472. doi: 10.1136/rmdopen-2024-004472
13. Gobierno de México.Diagnóstico y tratamiento de artritis reumatoide del adulto. Ciudad de México; Gov mex 2015. www.cenetec.salud.gov.mx
14. Weinstein A, McEVILLY B, Dervieux T. Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis. J Rheumatol 2019; 46 (6): 657-658. doi: 10.3899/jrheum.181246
15. Conigliaro P, Triggianese P, Chimenti MS, et al. Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors. Isr Med Assoc J 2017; 19 (8): 467-472.
16. Bird A, Oakden-Rayner L, Smith LA, et al. Prognostic modeling in early rheumatoid arthritis: reconsidering the predictive role of disease activity scores. Clin Rheumatol. 2024; 43 (5): 1503-1512. doi: 10.1007/s10067-024-06946-z
17. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther 2017; 19 (1): 68. doi: 10.1186/s13075-017-1266-4
18. Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2011; 70 (3): 469-475. doi: 10.1136/ard.2010.139212
19. Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. 2007; 100 (4): 193-201. doi: 10.1093/qjmed/hcm015
20. Harrold LR, Bryson J, Lehman T, et al. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA. Rheumatol Ther. 2021; 8 (2): 937-953. doi: 10.1007/s40744-021-00310-2
21. Frazzei G, Musters A, de Vries N, Tas SW, et al. Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals. Autoimmun Rev. 2023; 22 (1): 103217. doi: 10.1016/j.autrev.2022.103217
22. Javaid U, Mahmud TH, Rasheed A, Javaid AUR, et al. Factors Leading to Diagnostic and Therapeutic Delay of Rheumatoid Arthritis and Their Impact on Disease Outcome. Cureus. 2023; 15 (1): e34481. doi: 10.7759/cureus.34481
23. Maska LB, Sayles HR, O'Dell JR, et al. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64 (12): 1804-1810. doi: 10.1002/acr.21758
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México